EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Safety and Efficacy Comparison of Tenecteplase and Alteplase for Clinically Suspected Large Vessel Occlusion Strokes without Thrombectomy

Wai Ting Lo, Wing Chi Fong, Chris Siu Kwan Chau, Moamina Ismail, Jessica Tsz Ching Li, Chong Ching Chan, Chi Him Simon Chan, Chung Yuen Chan, Germaine Hui-Fai Chan, Andrew Lung-Tat Chan, Man Sin Wong, Wai Yan Vivian Kwok und 5 weitere

Cerebrovascular Diseases Extra · 2024

DOI: 10.1159/000540750 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cerebrovascular Diseases Extra, 2024. Verfasst von Wai Ting Lo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Tenecteplase, Fibrinolytic Agents, Ischemic Stroke, Thrombolytic Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tenecteplase is a thrombolytic with higher fibrin affinity and is potentially better in clot lysis. A higher spontaneous recanalisation rate for large vessel occlusion (LVO) strokes had been shown in comparison studies with alteplase. Results of the LVO studies reflect the composite effect of the thrombolytic and thrombectomy, as patients would be treated by thrombectomy had they not been recanalised by intravenous thrombolysis alone. Thrombectomy is not readily available in many parts of the world. Our study aimed to compare the outcomes of suspected LVO patients treated with tenecteplase versus alteplase only, without the confounding effect of thrombectomy.

Methods

This is a retrospective review. Data of patients given tenecteplase from May 2020 to August 2023 and those given alteplase 0.9 mg/kg from January 2019 to August 2023 were retrieved. Due to fluctuation in supply of tenecteplase during the COVID pandemic, some LVO patients were given alteplase. Patients with anterior circulation, clinically suspected LVO strokes (defined as National Institutes of Health Stroke Scale (NIHSS) score ≥6, plus cortical signs or hyperdense vessel sign), with thrombolysis given within 4.5 h of stroke onset were analysed. Patients with thrombectomy done were excluded. Safety and efficacy outcomes were compared.

Results

There were 245 tenecteplase-treated patients treated between May 1, 2020, and August 31, 2023, and 732 patients were treated with alteplase between January 1, 2019, to August 31, 2023. Out of these, 148 tenecteplase patients and 138 alteplase 0.9 mg/kg patients fulfilled the study criteria. The symptomatic intracerebral haemorrhage rate was non-significantly lower in the tenecteplase group (2.1% vs. 5.8%, p = 0.13). There were no significant differences in the rate of ≥8-point NIHSS improvement (23.6% vs. 23.7%, p = 1) or the ≥4-point improvement (40.5% vs. 40.7%, p = 1) at 24 h. At 3 months, 21.6% of tenecteplase patients had good functional outcome (modified Rankin scale [mRS] 0–2), compared to 26.3% in the alteplase group (p = 0.40).

Conclusion

In this pragmatic study of clinically suspected anterior circulation LVO patients without thrombectomy, outcome solely reflects the effects of tenecteplase. Tenecteplase showed comparable safety and efficacy to alteplase, but the result should be interpreted with caution in view of its small sample size and non-randomised study design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenecteplaseFibrinolytic AgentsIschemic StrokeThrombolytic TherapyTissue Plasminogen ActivatorHumansRetrospective StudiesMaleFemaleAgedTreatment OutcomeMiddle AgedTime FactorsAged, 80 and overRecovery of FunctionDisability EvaluationThrombectomy

Stichwörter der Autor:innen

Ischaemic strokeTenecteplaseThrombolysisTissue plasminogen activator

Substanzen

TenecteplaseFibrinolytic AgentsTissue Plasminogen Activator

Autor:innen und Institutionen

  • Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, China.

Zitieren

APA

Lo, W. T., Fong, W. C., Chau, C. S. K., Ismail, M., Li, J. T. C., Chan, C. C., Chan, C. H. S., Chan, C. Y., Chan, G. H., Chan, A. L., Wong, M. S., Kwok, W. Y. V., Or, H. F., Chan, S. T., Fong, C. S., Chan, N. M., & Cheung, Y. F. (2024). Safety and Efficacy Comparison of Tenecteplase and Alteplase for Clinically Suspected Large Vessel Occlusion Strokes without Thrombectomy. Cerebrovascular Diseases Extra. https://doi.org/10.1159/000540750

Vancouver

Lo WT, Fong WC, Chau CSK, Ismail M, Li JTC, Chan CC, et al. Safety and Efficacy Comparison of Tenecteplase and Alteplase for Clinically Suspected Large Vessel Occlusion Strokes without Thrombectomy. Cerebrovascular Diseases Extra. 2024. doi:10.1159/000540750

BibTeX
@article{Lo2024,
  author = {Lo, Wai Ting and Fong, Wing Chi and Chau, Chris Siu Kwan and Ismail, Moamina and Li, Jessica Tsz Ching and Chan, Chong Ching and Chan, Chi Him Simon and Chan, Chung Yuen and Chan, Germaine Hui-Fai and Chan, Andrew Lung-Tat and Wong, Man Sin and Kwok, Wai Yan Vivian and Or, Hiu Fan and Chan, Shun Tim and Fong, Ching Shing and Chan, Nga Man and Cheung, Yuk Fai},
  title = {Safety and Efficacy Comparison of Tenecteplase and Alteplase for Clinically Suspected Large Vessel Occlusion Strokes without Thrombectomy},
  journal = {Cerebrovascular Diseases Extra},
  year = {2024},
  doi = {10.1159/000540750}
}
Kostenlos starten →